Get the Stockscreener App
0.90
2.27%
0.02
Silo Pharma Inc stock is traded at $0.90, with a volume of 87,252.
It is up +2.27% in the last 24 hours and down -23.08% over the past month.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.
See More
Previous Close:
$0.88
Open:
$0.93
24h Volume:
87,252
Relative Volume:
0.50
Market Cap:
$4.08M
Revenue:
$72,100
Net Income/Loss:
$-3.60M
P/E Ratio:
-0.5357
EPS:
-1.68
Net Cash Flow:
$-3.37M
1W Performance:
-4.77%
1M Performance:
-23.08%
6M Performance:
-53.12%
1Y Performance:
-49.15%
1-Day Range:
$0.8506
$0.943
1-Week Range:
$0.77
$0.9878
52-Week Range:
$0.77
$4.50
Silo Pharma Inc Stock (SILO) Company Profile
Name
Silo Pharma Inc
Sector
Industry
Phone
(718) 400-9031
Address
677 N. WASHINGTON BLVD, SARASOTA
Compare SILO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SILO
SILO PHARMA INC
|
1.56 | 17.96M | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
21.49 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.14 | 315.71M | 2.07B | -1.42B | -1.37B | -0.1344 |
|
SHMD
Schmid Group N V
|
2.32 | 99.04M | 0 | 0 | 0 | 0.00 |
|
JUNE
Dhandho Junoon Etf
|
4.72 | 60.87M | 0 | 0 | 0 | 0.00 |
|
DAVEW
Dave Inc
|
0.155 | 0 | 0 | 0 | 0 | 0.00 |
Silo Pharma Inc Stock (SILO) Latest News
Silo Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Silo Pharma stock hits 52-week low at $0.83 amid market challenges - Investing.com Canada
Silo Pharma stock hits 52-week low at $0.83 amid market challenges By Investing.com - Investing.com South Africa
Silo Pharma CEO Eric Weisblum buys $4,625 in company stock - Investing.com
Silo Pharma Inc. Share PriceSILO, RNS News, Articles, Quotes, & Charts (NASDAQ: SILO) - Proactive Investors USA
Silo Pharma reports promising preclinical results in treating severe stress-related disorders - Proactive Investors UK
Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders - The Manila Times
Silo Pharma reports progress in PTSD treatment study - Investing.com
Silo Pharma Third Quarter 2024 Earnings: US$0.22 loss per share (vs US$0.21 loss in 3Q 2023) - Yahoo Finance
SILOSilo Pharma, Inc. Latest Stock News & Market Updates - StockTitan
Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant - GlobeNewswire
Silo Pharma, Inc. Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant - Marketscreener.com
Micron Technology (MU-Q) QuotePress Release - The Globe and Mail
Orange Juice (OJX25) Quote - The Globe and Mail
Japan Ice Bank Silo Market By Application - Third Eye News
SILO Pharma (NASDAQ:SILO) Stock Quotes, Forecast and News Summary - Benzinga
Exclusive Come Home Trailer Previews Horror Thriller Movie Featuring Silo Stars - ComingSoon.net
Egypt: General Company for Silos’s profits rise 45.6% YoY in FY2023/24 - ZAWYA
Silvis Materials Awarded $1 Million NSF SBIR Phase II Grant to Reduce Emissions in Packaging and Building - EIN News
FDA Grants Accelerated Approval to Gilead’s Livdelzi for Primary Biliary Cholangitis - The Healthcare Technology Report.
Serpin Pharma and Uniklinikum Erlangen Team Up for a Clinical Trial to Prevent Acute Kidney Injury - EIN News
New Silo Season 2 Character Is Very Closely Copying An Iconic 2000s TV Show - Screen Rant
Roli Mosimann (Swans / Wiseblood / The The) has died - Brooklyn Vegan
SosMula Finally Delivers "SLEEZ RELIGION" - HotNewHipHop
Silo season 2: Apple TV Plus release date, likely cast, story rumors, and more news about the sci-fi show's return - TechRadar
Silo Pharma completes pre-IND meeting with FDA on SPC-15 for PTSD - BioWorld Online
Financial Metrics Exploration: Understanding SILO Pharma Inc (SILO) Through Ratios - The Dwinnex
SILO Pharma Inc [SILO] Insider Activity: An Update for Investors - Knox Daily
Silo Pharma moves forward with PTSD treatment SPC-15 - Investing.com
Silo Pharma moves forward with PTSD treatment SPC-15 By Investing.com - Investing.com Australia
SILO Pharma Inc Inc. (SILO) Price Performance: A Technical Analysis Perspective - The InvestChronicle
SILO’s price-to-sales ratio: Is it a good investment opportunity? - US Post News
Silo Pharma Outlines Strategic Direction and Innovative Pipeline - TipRanks
Silo Pharma Announces Completion of FDA Pre-IND Meeting to - GlobeNewswire
Psychedelic Drugs Market to Grow by USD 1.37 Billion from 2024-2028, Driven by Increasing Mental Health Disorders, Report Highlights AI's Impact on the Market LandscapeTechnavio - The Malaysian Reserve
Silo Pharma (NASDAQ:SILO) Shares Down 6% - Defense World
Adversity is less terrifying than hope: SILO Pharma Inc (SILO) - SETE News
SILO Pharma Inc (SILO)’s stock price range in the last year - US Post News
Metric Deep Dive: Understanding SILO Pharma Inc (SILO) Through its Ratios - The Dwinnex
SILO Pharma Inc [SILO] Investment Guide: What You Need to Know - Knox Daily
SciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million - Quantisnow
SILO’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Silo Pharma advances ketamine implant for chronic pain treatment - Investing.com India
Silo Pharma Shares Jump 11% on Ketamine-Treatment Partnership - MarketWatch
Silo Pharma advances ketamine implant for chronic pain treatment By Investing.com - Investing.com UK
Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic - GlobeNewswire
SILO Pharma Inc’s latest rating changes from various analysts - Knox Daily
Silo Pharma partners with WuXi AppTec for MS peptide study - Investing.com India
Closing Figures: SILO Pharma Inc (SILO)’s Negative Finish at 1.18, Down -13.24 - The Dwinnex
Silo Pharma partners with WuXi AppTec for MS peptide study By Investing.com - Investing.com UK
SILO’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle
Silo Pharma Inc Stock (SILO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Silo Pharma Inc Stock (SILO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Weisblum Eric | CEO and President |
Nov 22 '24 |
Buy |
0.90 |
2,500 |
2,250 |
185,432 |
| Weisblum Eric | CEO and President |
Jun 12 '24 |
Buy |
1.11 |
4,438 |
4,926 |
180,432 |
| Weisblum Eric | CEO and President |
Jun 11 '24 |
Buy |
1.08 |
562 |
607 |
175,994 |
| Weisblum Eric | CEO and President |
Apr 04 '24 |
Buy |
1.96 |
600 |
1,176 |
175,032 |
| Weisblum Eric | CEO and President |
Apr 05 '24 |
Buy |
2.03 |
400 |
812 |
175,432 |
| Weisblum Eric | CEO and President |
Mar 28 '24 |
Buy |
1.94 |
3,408 |
6,612 |
173,332 |
| Weisblum Eric | CEO and President |
Apr 01 '24 |
Buy |
1.91 |
1,100 |
2,101 |
174,432 |
| Weisblum Eric | CEO and President |
Dec 19 '23 |
Buy |
1.63 |
500 |
815 |
169,724 |
| Weisblum Eric | CEO and President |
Dec 20 '23 |
Buy |
1.61 |
200 |
322 |
169,924 |
| Weisblum Eric | CEO and President |
Dec 15 '23 |
Buy |
1.52 |
900 |
1,368 |
169,224 |
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):